Investigating how cancer cells produce unique proteins in non-small cell lung cancer
Alternate splicing as a source of shared neoantigens in a non-small cell lung cancer
This study is looking at ways to make current treatments for non-small cell lung cancer work better by creating special vaccines that help your immune system recognize and fight the cancer cells more effectively, especially for those who haven't had success with standard therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project ID | NIH-10884212 on NIH RePORTER |
What this research studies
This research focuses on non-small cell lung cancer (NSCLC), a leading cause of cancer deaths. It aims to enhance the effectiveness of existing immunotherapies by developing cancer vaccines that target unique proteins, known as neoantigens, produced by cancer cells through a process called alternative splicing. By using advanced RNA sequencing techniques, the researchers will identify these neoantigens and assess their potential to stimulate the immune system, specifically CD8+ T cells, to attack tumor cells more effectively. The goal is to improve treatment responses for patients who currently do not benefit from standard therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer who are seeking new treatment options.
Not a fit: Patients with other types of lung cancer or those who are not diagnosed with cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer vaccines that improve survival rates for patients with non-small cell lung cancer.
How similar studies have performed: Previous research has shown promise in targeting neoantigens for cancer treatment, indicating that this approach could be a significant advancement in cancer immunotherapy.
Where this research is happening
Farmington, United States
- University of Connecticut Sch of Med/dnt — Farmington, United States (Active)
Researchers
- Principal investigator: Englander, Ryan — University of Connecticut Sch of Med/dnt
- Study coordinator: Englander, Ryan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.